TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $65,887,800 | -41.8% | 7,370,000 | 0.0% | 2.54% | -51.5% |
| Q2 2023 | $113,203,200 | -18.1% | 7,370,000 | +19.9% | 5.24% | -7.7% |
| Q1 2023 | $138,252,057 | +43.5% | 6,147,268 | +34.2% | 5.68% | +40.3% |
| Q4 2022 | $96,359,460 | -2.2% | 4,582,000 | +14.6% | 4.05% | -10.4% |
| Q3 2022 | $98,560,000 | +13.6% | 4,000,000 | +11.7% | 4.51% | -20.8% |
| Q2 2022 | $86,760,000 | +7.4% | 3,580,700 | +14.2% | 5.70% | +10.1% |
| Q1 2022 | $80,776,000 | +6.2% | 3,134,503 | +27.9% | 5.18% | -3.5% |
| Q4 2021 | $76,048,000 | – | 2,450,000 | – | 5.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |